Rapporto sull’analisi delle quote e delle dimensioni del mercato delle malattie cardiometaboliche | Previsioni 2031

  • Report Code : TIPRE00025374
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 293
Buy Now

Si prevede che il mercato delle malattie cardiometaboliche raggiungerà i 121.804,49 milioni di dollari entro il 2028 rispetto ai 93.494,41 milioni di dollari del 2021; si stima che crescerà a un CAGR del 3,9% nel corso del 2021-2028.

Le malattie cardiometaboliche sono caratterizzate da un gruppo di anomalie e sintomi che aumentano il rischio che gli individui sviluppino malattia cardiovascolare. Ipertensione, obesità, resistenza all’insulina, dislipidemia, basso profilo di colesterolo (LDL) e tolleranza al glucosio sono alcuni sintomi di malattie cardiometaboliche. Gli individui che soffrono di sindrome cardiometabolica sono soggetti a molte altre malattie potenzialmente letali, come il diabete di tipo 2, l’ictus, la malattia coronarica (CAD) e le malattie cardiovascolari (CVD). Sia le condizioni genetiche che quelle ambientali sono responsabili dello sviluppo delle malattie.

Approfondimenti strategici

La crescita del mercato delle malattie cardiometaboliche è principalmente attribuita a fattori quali come la crescente prevalenza delle malattie cardiometaboliche e l’innovazione nelle terapie per le CMD. Tuttavia, la sottodiagnosi delle malattie cardiovascolari nei paesi a basso e medio reddito (LMIC) sta ostacolando la crescita del mercato.

Regioni redditizie nel mercato delle malattie cardiometaboliche


< /h3>

Approfondimenti di mercato
Aumento della prevalenza delle malattie cardiometaboliche

Le malattie cardiometaboliche (CMD) sono una delle principali cause di morte in tutto il mondo. Queste malattie sono causate principalmente da uno stile di vita non sano, dall’inattività fisica, dal fumo e da una dieta non sana. Le CMD comprendono le malattie cardiovascolari (CVD), il diabete mellito e l’insufficienza renale cronica. Secondo l’OMS, nel 2019 sono morte a causa di malattie cardiovascolari circa 17,9 milioni di persone, che rappresentano il 32% di tutti i decessi globali. Di questi decessi, l'85% era dovuto a infarto e ictus.

La maggior parte delle malattie cardiovascolari può essere prevenuta affrontando i fattori di rischio comportamentali, come l'assunzione di tabacco, scelte alimentari non salutari, obesità, sedentarietà e il consumo di alcol. Il diabete è una delle malattie croniche potenzialmente letali senza cura funzionale. Porta a varie complicazioni e aumenta il rischio complessivo di morte prematura. Infarto, ictus, insufficienza renale, amputazione delle gambe, perdita della vista e danni ai nervi sono le principali complicanze associate al diabete. Secondo l'International Diabetes Federation (IDF), nel 2019, circa 463 milioni di adulti convivevano con il diabete, cifra che si prevede raggiungerà i 700 milioni entro il 2045.

Esiste un aumento globale del numero di persone affette da una o più CMD a causa dell’aumento del fumo, della mancanza di esercizio fisico, del consumo di alcol e di abitudini alimentari non salutari. Secondo le statistiche dell’OMS di luglio 2021, più di 8 milioni di persone muoiono ogni anno a causa del consumo di tabacco. Il suo consumo è più elevato nei paesi a basso e medio reddito, dove l’80% della base di consumatori globale vive in questi paesi. La crescente prevalenza dell’obesità sta facendo crescere anche una base di pazienti che soffre di CMD. Con questo rapido aumento della prevalenza delle CMD, la necessità di trattamenti adeguati per le malattie cardiometaboliche è salita alle stelle, determinando un'enorme crescita del mercato.

Approfondimenti basati sul tipo

Il mercato delle malattie cardiometaboliche, per tipologia, è segmentato in malattie cardiovascolari (CVD), ipertensione, diabete di tipo 2 e obesità. Il segmento delle malattie cardiovascolari (CVD) ha detenuto la quota maggiore del mercato nel 2021 e si prevede che registrerà il CAGR più elevato sul mercato durante il periodo di previsione.

Mercato delle malattie cardiometaboliche, per tipo: 2021 e 2028


Approfondimenti basati sul trattamento

In base al trattamento, il mercato delle malattie cardiometaboliche è segmentato in ACE inibitori, diuretici, Glucophage e altri. Il segmento degli ACE inibitori ha detenuto la quota maggiore del mercato nel 2021 e si prevede che lo stesso segmento registrerà il CAGR più elevato sul mercato durante il periodo di previsione.

Approfondimenti basati sul dosaggio

Il mercato delle malattie cardiometaboliche, in base al dosaggio, è diviso in compresse e iniezioni. Il segmento dei tablet ha detenuto una quota di mercato maggiore nel 2021 e si prevede che registrerà un CAGR più elevato nel mercato durante il periodo di previsione.

Percorso di approfondimenti basati sull'amministrazione

Il mercato delle malattie cardiometaboliche, per via di somministrazione, è diviso in orale ed endovenoso. Nel 2021, il segmento orale deteneva una quota maggiore del mercato e si prevede che registrerà un CAGR più elevato nei prossimi anni.

Approfondimenti basati sugli utenti finali

Il mercato delle malattie cardiometaboliche, in base agli utenti finali, è segmentato in ambito clinico, ospedaliero e domiciliare. Nel 2021, il segmento ospedaliero deteneva la quota maggiore del mercato e si prevede che registrerà il CAGR più elevato del mercato durante il periodo di previsione.


Il lancio e l'approvazione dei prodotti sono strategie comunemente adottate dalle aziende per espandere la propria presenza globale e i portafogli di prodotti. Inoltre, gli operatori del mercato di prova sviluppato in laboratorio si concentrano sulla strategia di partnership per ampliare la propria clientela, che, a sua volta, consente loro di mantenere il proprio marchio a livello globale.

Il rapporto segmenta il mercato delle malattie cardiometaboliche come segue

In base alla tipologia, il mercato delle malattie cardiometaboliche è segmentato in malattie cardiovascolari (CVD), ipertensione, diabete di tipo 2 e obesità. In base al trattamento, il mercato è segmentato in ACE inibitori, diuretici, Glucophage e altri. In base al dosaggio, il mercato delle malattie cardiometaboliche è diviso in compresse e iniezioni. In base alla via di somministrazione, il mercato è diviso in orale ed endovenosa. In base agli utenti finali, il mercato delle malattie cardiometaboliche è segmentato in ambito clinico, ospedaliero e domiciliare. Per area geografica, il mercato è segmentato in Nord America (Stati Uniti, Canada e Messico), Europa (Regno Unito, Germania, Francia, Italia, Spagna e resto d’Europa), Asia Pacifico (Cina, Giappone, India, Australia , Corea del Sud e resto dell'Asia Pacifico), Medio Oriente e Africa (EAU, Arabia Saudita, Sud Africa e resto del Medio Oriente e Africa) e America meridionale e centrale (Brasile, Argentina e Paesi Bassi). Resto dell'America centrale e meridionale).

Profili aziendali

  • Eli Lilly and Company< /li>
  • Bayer AG
  • Arrowhead Pharmaceuticals, Inc
  • Novartis AG
  • Boehringer Ingelheim International GmbH
  • Novo Nordisk A/ S
  • AstraZeneca
  • Alnylam Pharmaceuticals, Inc.
  • Cardax, Inc
  • Kowa Company, Ltd.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is cardiometabolic diseases market?

Cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are a few symptoms of cardiometabolic diseases. Individuals suffering from cardiometabolic syndrome are prone to many other life-threatening diseases, such as type 2 diabetes, stroke, coronary artery disease (CAD), and cardiovascular disease (CVD). Both genetic and environmental conditions are responsible for the development of the diseases.

What are the driving factors for the cardiometabolic diseases market across the country?

The factors that are driving and restraining factors that will affect cardiometabolic diseases market in the coming years. Factors such as increasing prevalence of cardiometabolic diseases and innovation in CMDs therapeutics. However, underdiagnosis of CVDs in low- and middle-income countries (LMICs) is hampering the growth of the market.

Who are the major players in the cardiometabolic diseases market?

The cardiometabolic diseases market majorly consists of the players such as as Eli Lilly and Company; Bayer AG; Arrowhead Pharmaceuticals, Inc; Novartis AG; Boehringer Ingelheim International GmbH; Novo Nordisk A/S; AstraZeneca; Alnylam Pharmaceuticals, Inc.; Cardax, Inc.; and Kowa Company, Ltd among others.

Which segment is dominating the cardiometabolic diseases market?

The global cardiometabolic diseases market cardiovascular disease (CVD), hypertension, type 2 diabetes, and obesity. The cardiovascular disease (CVD) segment is expected to hold the largest share and register the highest CAGR in the market during the forecast period.

The List of Companies - Cardiometabolic Diseases Market

  1. Eli Lilly and Company
  2. Bayer AG
  3. Arrowhead Pharmaceuticals, Inc
  4. Novartis AG
  5. Boehringer Ingelheim International GmbH
  6. Novo Nordisk A/S
  7. AstraZeneca
  8. Alnylam Pharmaceuticals, Inc.
  9. Cardax, Inc
  10. Kowa Company, Ltd.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports